Response and progression in recurrent malignant glioma

Neuro-Oncology

Volumn 1, Issue 4, 1999, Pages 282-288

  Hess, Kenneth R ^a,c   Wong, Eric T ^a   Jaeckle, Kurt A ^a   Kyritsis, Athanassios P ^a   Levin, Victor A ^a   Prados, Michael D ^b   Yung, W K Alfred ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ANTINEOPLASTIC AGENT; BETA INTERFERON; CARBOPLATIN; EFLORNITHINE; FLUOROURACIL; MENOGARIL; PROCARBAZINE; RETINOIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES;

ACTUARIAL ANALYSIS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CARBOPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EFLORNITHINE; FEMALE; FLUOROURACIL; GLIOBLASTOMA; GLIOMA; HUMANS; INTERFERON-BETA; MALE; MENOGARIL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROCARBAZINE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TEXAS; TREATMENT OUTCOME; TRETINOIN;

EID: 0033206868     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-1-4-282     Document Type: Article

References (27)

1. A'Hern, R.P., Ebbs, S.R., and Baum M.B. (1988) Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br. J. Cancer 57, 615-618.
2. Anderson, J.R., Cain, K.C., and Gelber, R.D. (1983) Analysis of survival by tumor response. J. Clin. Oncol. 1, 710-719.
3. Anderson, J.R., Cain, K.C., Gelber, R.D., and Gelman, R.S. (1985) Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials. Cancer Treat. Rep. 69, 1139-1146.
4. Bull, K., and Spiegelhalter, D.J. (1997) Survival analysis in observational studies. Stat. Med. 16, 1041-1074.
5. Buyse, M., and Piedbois, P. (1996) On the relationship between response to treatment and survival time. Stat Med. 15, 2797-2812.
6. Cnaan, A., and Ryan, L. (1989) Survival analysis in natural history studies of disease. Stat. Med. 8, 1255-1268.
7. Cox, D.R. (1972) Regression models and life tables (with discussion). J. Royal Stat. Soc. B 74, 187-220.
8. Eagan, R.T., and Scott, M. (1983) Evaluation of prognostic factors in chemotherapy of recurrent brain tumors. J. Clin. Oncol. 1, 38-44.
9. Feuer, E.J., Hankey, B.F., Gaynor, J.J., Wesley, M.N., Baker, S.G., and Meyer, J.S. (1992) Graphical representation of survival curves associated with a binary non-reversible time dependent covariate. Stat. Med. 11, 455-474.
10. Fine, H.A. (1994) The basis for current treatment recommendations for malignant gliomas. J. Neurooncol. 20, 111-120.
11. Graf, W., Pahlman, L., Bergstrom, R., and Glimelius, B. (1994) The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br. J. Cancer 70, 559-563.
12. Grambsch, P.M., and Therneau, T.M. (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81, 515-526.
13. Grant, R., Liang, B.C., Slattery, J., Greenberg, H.S., and Junck, L. (1997) Chemotherapy response criteria in malignant glioma. Neurology 48, 1336-1340.
14. Hess, K.R. (1995) Graphical methods for assessing violations of the proportional hazards assumptions in Cox regression. Stat. Med. 14, 1707-1723.
15. Kaplan, E.L., and Meier, P. (1958) Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481.
16. Klein, J.P., and Moeschberger, M.L. (1997) Survival Analysis: Techniques for Censored and Truncated Data. New York: Springer. pp. 153, 271, 276.
17. Leventhal, B.G., and Wittes, R.E. (1988) Research Methods in Clinical Oncology. New York: Raven Press. pp. 69-70.
18. Macdonald, D.R., Cascino, T.L., Schold, S.C., Jr., and Cairncross, J.G. (1990) Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280.
19. Pepe, M.S., and Cai, J. (1993) Some graphical displays and marginal regression analyses for recurrent failure times and time dependent covariates (in theory and methods). J. Am. Stat. Assoc. 88, 811-820.
20. Perry, J.R., DeAngelis, L.M., Schold, S.C., Jr., Burger, P.C., Brem, H., Brown, M.T., Curran, W.J., Scott, C.B., Prados, M.D., Kaplan, R., and Cairncross, J.G. (1997) Challenges in the design and conduct of phase III brain tumor therapy trials. Neurology 49, 912-917.
21. Rajan, B., Ross, G., Lim, C.C., Ashley, S., Goode, D., Traish, D., and Brada, M. (1994) Survival in patients with recurrent glioma as a measure of treatment efficacy: Prognostic factors following nitrosourea chemotherapy. Eur. J. Cancer 30A, 1809-1815.
22. Simon, R., and Makuch, R.W. (1984) A non-parametric graphical representation of the relationship between survival and the occurrence of an event Application to responder versus non-responder bias. Statis. Med. 3, 35-44.
23. Slack, N.H., Mittelman, A., Brady, M.F., and Murphy, G.P. (1980) The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer. Cancer 46, 2393-2402.
24. Torri, V., Simon, R., Russek-Cohen, E., Midthune, D., and Friedman, M. (1992) Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. J. Natl. Cancer Inst. 84, 407-414.
25. Wand, M.P., and Jones, M.C. (1997) Kernel Smoothing. Second edition. New York: Chapman and Hall.
26. Weiss, G.B., Bunce, H., III, and Hokanson, J.A. (1983) Comparing survival of responders and nonresponders after treatment: A potential source of confusion in interpreting cancer clinical trials. Control. Clin. Trials 4, 43-52.
27. Wong, E.T., Hess, K.R., Gleason, M.J., Jaeckle, K.A., Kyritsis, A.P., Prados, M.D., Levin, V.A., and Yung, W.K.A. (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled in phase II clinical trials. J. Clin. Oncol. 17, 2572-2578.